title: Large volume loading to prevent cisplatin-induced nephrotoxicity during negative-balance isolated pelvic perfusion.
abstract: OBJECTIVE
  Negative-balance isolated pelvic perfusion (NIPP) is used to administer high doses of anticancer drugs such as cisplatin to patients with advanced cancer of the pelvic region. Although the drugs are intended to be specifically delivered to the pelvis, their leakage into the systemic circulation can cause acute renal failure. This study examines the loading volume required for preservation of renal function during anesthesia of NIPP.
  
  
  METHODS
  Pelvic cancer patients were assigned to NIPP according to its enrollment criteria. Patients with heart failure, uncontrollable hypertension, renal failure, pulmonary disease or contraindication for the contrast media were excluded. We compared the current anesthesia management regime with a previous protocol, with regard to the loading volume and renal function as assessed by the calculated glomerular filtration rate (GFR). The correlation between the total loading volume and the GFR ratio (GFR after NIPP/GFR before NIPP) was evaluated to define adequate volume loading.
  
  
  RESULTS
  The GFR ratios were 0.86 +/- 0.29 and 1.12 +/- 0.25 for the previous and current procedures, respectively. The regression line showed that a minimum loading volume of 28.8 ml kg(-1) h(-1) was required to maintain a GFR ratio of > or =1.
  
  
  CONCLUSIONS
  A large volume infusion preserves the GFR despite high-dose cisplatin administration by NIPP.
authors.affiliation: Department of Anesthesiology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, 113-8602, Tokyo, Japan. k-nakazato@nms.ac.jp
authors.forename: Keiko
authors.initials: K
authors.lastname: Nakazato
authors.forename: Chol
authors.initials: C
authors.lastname: Kim
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Terajima
authors.forename: Satoru
authors.initials: S
authors.lastname: Murata
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Fujitani
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Nakanishi
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Tajima
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Kumazaki
authors.forename: Atsuhiro
authors.initials: A
authors.lastname: Sakamoto
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000009:adverse effects* / Q000379:methods*; D002945:Cisplatin / Q000008:administration & dosage*; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D010388:Pelvis / Q000098:blood supply; D010477:Perfusion
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin